Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory
Table 2
Baseline characteristics of 62 TB/HIV coinfected patients from Minsk, Belarus, stratified according to availability of Mycobacterium tuberculosis (Mtb) culture sample.
Total
Sample yes, (%)
Sample no, (%)
30
32
Gender
Male, (%)
22 (73)
28 (88)
0.206
Age
Years, median (IQR)
37 (30-41)
35 (32-42)
0.789
TB/HIV risk factors
Ever injecting drug use, (%)
19 (63)
24 (75)
0.319
History of imprisonment, (%)
5 (17)
12 (38)
0.090
History of excess alcohol consumption, (%)
19 (63)
15 (47)
0.213
Mtb culture positive
Yes, (%)
30 (100)
25 (78)
0.0015
MDR-TB
Yes, (%)
18 (60)
16 (50)
0.456
TB disease
Disseminated, (%)
12 (40)
6 (19)
0.060
Hepatitis C
Ever, (%)
24 (80)
23 (72)
0.454
HIV duration prior to TB
Months, median (IQR)
88 (44-136)
67 (25-120)
0.535
Antiretroviral therapy at baseline
Yes, (%)
15 (50)
14 (44)
0.622
CD4 count
Cells/mm3, median (IQR)
85 (22-171)
126 (57-310)
0.097
Abbreviations: baseline = date of TB diagnosis; IQR = interquartile range; = number; MDR-TB = multidrug-resistant TB; Mtb = Mycobacterium tuberculosis; TB = tuberculosis; Hepatitis C antibody positive.